Development of α-melanocortin analogs for melanoma prevention and targeting

Advances in Experimental Medicine and Biology

Volumn 681, Issue , 2010, Pages 126-132

  Abdel Malek, Zalfa A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ACETYL 4 NORLEUCINE 7 DEXTRO PHENYLALANINE ALPHA INTERMEDIN; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ACETYL 4 NORLEUCINE 7 DEXTRO PHENYLALANINE ALPHA INTERMEDIN IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BETA ALANYLNORLEUCYLASPARTYL DEXTRO PHENYLALANYLLYSINE ALPHA INTERMEDIN; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BETA ALANYLNORLEUCYLASPARTYL DEXTRO PHENYLALANYLLYSINE ALPHA INTERMEDIN IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID NORLEUCYLASPARTYL DEXTRO PHENYLALANINE ALPHA INTERMEDIN; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID NORLEUCYLASPARTYL DEXTRO PHENYLALANINE ALPHA INTERMEDIN IN 111; 5 PHENYLBUTYRYL DERIVATIVE; ACETYL 4 NORLEUCINE 7 DEXTRO PHENYLALANINE ALPHA INTERMEDIN; ACETYL 4 NORLEUCINE [ASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHANYLLYSINE] AMIDE; ACETYLCYSTEINYLCYSTEINE ALPHA INTERMEDIN; ALPHA INTERMEDIN; ALPHA INTERMEDIN DERIVATIVE; BETA ALANYLNORLEUCYLASPARTYL DEXTRO PHENYLALANYLLYSINE ALPHA INTERMEDIN; BETA ALANYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHANYLLYSINE AMIDE TC 99M; COSMETIC; EUMELANIN; LK 184; MELANOCORTIN RECEPTOR AGONIST; MELANOTAN II; MELANOTAN II TC 99M; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; N PENTADECANOYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHAN AMIDE; N PHENYLBUTYRYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHAN AMIDE; NORLEUCYLASPARTYL DEXTRO PHENYLALANINE ALPHA INTERMEDIN; PHEOMELANIN; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CONTROL; CANCER PREVENTION; DIAGNOSTIC IMAGING; DNA DAMAGE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; IN VIVO STUDY; KIDNEY CLEARANCE; MELANOGENESIS; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; SKIN CANCER; SKIN METASTASIS; SKIN PIGMENTATION; SKIN PROTECTION; TRANSDERMAL PATCH; TUMOR LOCALIZATION; ULTRAVIOLET RADIATION;

AMINO ACID SEQUENCE; ANIMALS; DNA DAMAGE; DRUG DISCOVERY; HUMANS; MELANOCORTINS; MELANOMA; MOLECULAR TARGETED THERAPY; ULTRAVIOLET RAYS;

VERTEBRATA;

EID: 79959561922     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6354-3_10     Document Type: Article

References (49)

1. Sawyer TK, Hruby VJ, Hadley ME et al. α-Melanocyte stimulating hormone: Chemical nature and mechanism of action. Am Zool 1983; 23:529-540.
2. Levine N, Lemus-Wilson AL, Wood SH et al. Stimulation of follicular melanogenesis in the mouse by topical and injected melanotropins. J Invest Dermatol 1987; 89:269-273. (Pubitemid 17126579)
3. Tamate HB, Takeuchi T. Action of the e locus of mice in the response of phaeomelanic hair follicles to α-melanocyte-stimulating hormone in vitro. Science 1984; 224:1241-1242. (Pubitemid 14109461)
4. Lerner AB, McGuire JS. Effect of alpha- and beta-melanocyte stimulating hormones on the skin colour of man. Nature 1961; 189:176-179.
5. Mountjoy KG, Robbins LS, Mortrud MT et al. The cloning of a family of genes that encode the melanocortin receptors. Science 1992; 257:1248-1251.
6. Chhajlani V, Wikberg JES. Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA. FEBS Lett 1992; 309:417-420.
7. Abdel-Malek Z, Swope VB, Suzuki I et al. Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci USA 1995; 92:1789-1793.
8. Hunt G, Donatien PD, Lunec J et al. Cultured human melanocytes respond to MSH peptides and ACTH. Pigment Cell Res 1994; 7:217-221.
9. Suzuki I, Cone R, Im S et al. Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology 1996; 137:1627-1633. (Pubitemid 26133934)
10. Ghanem GE, Comunale G, Libert A et al. Evidence for alpha-melanocyte stimulating hormone receptors on human malignant melanoma cells. Int J Cancer 1988; 41:248-255. (Pubitemid 18061152)
11. Hadley ME. Endocrinology. 4th ed. Upper Saddle River, NJ: Prentice-Hall, Inc., 1996.
12. Pathak MA, Fitzpatrick TB. The role of natural photoprotective agents in human skin. In: Fitzpatrick TB, Pathak MA, Haber LC et al, eds. Sunlight and Man. Tokyo: University of Tokyo Press, 1974; 725-750.
13. Kaidbey KH, Poh Agin P, Sayre RM et al. Photoprotection by melanin-a comparison of black and Caucasian skin. J Am Acad Dermatol 1979; 1:249-260. (Pubitemid 11159972)
14. Sawyer TK, Sanfilippo PJ, Hruby VJ et al. 4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: A highly potent α-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA 1980; 77:5754-5758. (Pubitemid 11206397)
15. Marwan MM, Abdel-Malek ZA, Kreutzfeld KL et al. Stimulation of S91 melanoma tyrosinase activity by superpotent α-melanotropins. Mol Cell Endocrinol 1985; 41:171-177. (Pubitemid 15022741)
16. 7]-α-MSH: A superpotent melanotropin that "irreversibly" activates melanoma tyrosinase. Endocr Res 1985; 11:157-170. (Pubitemid 16126188)
17. 7]-substituted α-melanotropins. Cancer Res 1985; 45:4735-4740. (Pubitemid 16236140)
18. Abdel-Malek ZA, Kadekaro AL, Kavanagh RJ et al. Melanoma prevention strategy based on using tetrapeptide alpha-MSH analogs that protect human melanocytes from UV-induced damage and cytotoxicity. FASEB J 2006; 20:1561-1563.
19. Levine N, Sheftel SN, Eytan T et al. Induction of skin tanning by the subcutaneous administration of a potent synthetic melanotropin. JAMA 1991; 266:2730-2736.
20. 7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol 2006; 126(8):1869-1878. (Pubitemid 44086522)
21. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization. Peptides 2006; 27(4):921-930.
22. Gehlsen KR, Hadley ME, Levine N et al. Effects of a melanotropic peptide on melanoma cell growth, metastasis and invasion. Pigment Cell Res 1992; 5:219-223.
23. Paine-Murrieta GD, Taylor CW, Curtis RA et al. Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol 1997; 40(3):209-214. (Pubitemid 27257733)
24. 7] alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation. Pigment Cell Res 1995; 8(6):314-323.
25. Sawyer TK, Hruby VJ, Wilkes BC et al. Comparative biological activities of highly potent active-site analogues of α-melanotropin. J Med Chem 1982; 25:1022-1027. (Pubitemid 13233571)
26. Al-Obeidi F, Castrucci AM, Hadley ME et al. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: Design based on molecular dynamics. J Med Chem 1989; 32(12):2555-2561. (Pubitemid 20002805)
27. 7,Lys10]-α- MSH(4-10)-NH-2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem 1995; 38:3454-3461.
28. Holder JR, Bauzo RM, Xiang Z et al. Design and pharmacology of peptoids and peptide-peptoid hybrids based on the melanocortin agonists core tetrapeptide sequence. Bioorg Med Chem Lett 2003; 13(24):4505-4509. (Pubitemid 37490846)
29. Kadekaro AL, Kavanagh R, Kanto H et al. α-melanocortin and endothelin-1 activate anti-apoptotic pathways and reduce DNA damage in human melanocytes. Cancer Res 2005; 65:4292-4299. (Pubitemid 40775668)
30. Song X, Mosbi N, Yang J et al. Alpha-MSH activates immediate defense responses to UV-induced oxidative stress in human melanocytes. Pigment Cell Mel Res 2009, In press.
31. Bohm M, Wolff I, Scholzen TE et al. Alpha-melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem 2005; 280(7):5795-5802. (Pubitemid 40280060)
32. Smith AG, Luk N, Newton RA et al. Melanocortin-1 receptor signaling markedly induces the expression of the NR4A nuclear receptor subgroup in melanocytic cells. J Biol Chem 2008; 283(18):12564-12570.
33. 2]. An additional binding site within the human melanocortin receptor 1? Bioorgan Med Chem Lett 2004; 14:3997-4000. (Pubitemid 38844412)
34. 2 tetrapeptides: Influence of fatty acid chain length on potency and selectivity at the mouse melanocortin receptors and human melanocytes. J Med Chem 2005; 48:3328-3336. (Pubitemid 40628051)
35. Abdel-Malek ZA, Ruwe AR, Kavanagh-Starner R et al. α-MSH tripeptide analogs activate the melanocortin 1 receptor and reduce UV-induced DNA damage in human melanocytes. Pigment Cell Mel Res 2009, In press.
36. Box NF, Wyeth JR, O'Gorman LE et al. Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum Mol Genet 1997; 6:1891-1897. (Pubitemid 27460365)
37. Smith R, Healy E, Siddiqui S et al. Melanocortin 1 receptor variants in Irish population. J Invest Dermatol 1998; 111:119-122. (Pubitemid 28309219)
38. Palmer JS, Duffy DL, Box NF et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: Is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000; 66:176-186. (Pubitemid 30481481)
39. Kennedy C, ter Huurne J, Berkhout M et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001; 117:294-300. (Pubitemid 34205714)
40. van der Velden PA, Sandkuijl LA, Bergman W et al. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 2001; 69:774-779. (Pubitemid 32868522)
41. Froidevaux S, Calame-Christe M, Tanner H et al. A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med 2002; 43(12):1699-1706. (Pubitemid 35424997)
42. Cheng Z, Zhang L, Graves E et al. Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog. J Nucl Med 2007; 48(6):987-994. (Pubitemid 46909928)
43. Froidevaux S, Calame-Christe M, Schuhmacher J et al. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004; 45(1):116-123. (Pubitemid 47611617)
44. Bapst JP, Calame M, Tanner H et al. Glycosylated DOTA-alpha-melanocyte- stimulating hormone analogues for melanoma targeting: Influence of the site of glycosylation on in vivo biodistribution. Bioconjug Chem 2009.
45. 3]: Effect of cyclization on tumor-seeking properties. J Biol Inorg Chem 2008; 13(3):449-459.
46. Miao Y, Quinn TP. Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol Hematol 2008; 67(3):213-228.
47. Bohm M, Schiller M, Stander S et al. Evidence for expression of melanocortin-1 receptor in human sebocytes in vitro and in situ. J Invest Dermatol 2002; 118(3):533-539. (Pubitemid 34227173)
48. Thiboutot D, Sivarajah A, Gilliland K et al. The melanocortin 5 receptor is expressed in human sebaceous glands and rat preputial cells. J Invest Dermatol 2000; 115(4):614-619.
49. Roberts DW, Newton RA, Beaumont KA et al. Quantitative analysis of MC1R gene expression in human skin cell cultures. Pigment Cell Res 2006; 19(1):76-89.